42 completed, 5 unknown, 3 recruiting, 1 active not recruiting. 53 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 53 | Completed 42, Unknown 5, Recruiting 3, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 12 | Completed 8, Recruiting 2, Active not recruiting 1, Terminated 1 |
Follow Picornaviridae Infections: new trials by email Literature Review of Picornaviridae Infections trials Research Report on Picornaviridae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults Recombinant Poliomyelitis Vaccine (rPV), Inactivated Poliomyelitis Vaccine (IPOL) - Polio Immunity | Phase 1 | Recruiting | Serum Institute of India Pvt. Ltd. | 36 | 2026-09-11 | 2026-09-29 |
| Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine Low Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell), Medium Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell), High Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell) - Hand, Foot and Mouth Disease (HFMD), HFMD | Phase 1 | Not yet recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 144 | 2025-12-30 | 2026-01-08 |
| Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell), Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell), High-dose tetravalent inactivated enterovirus vaccine (Vero cell) ) - Hand, Foot, and Mouth Disease (HFMD), Herpangina | Phase 1 / Phase 2 | Completed | Sinovac Biotech Co., Ltd | 552 | 2025-01-15 | 2026-03-04 |
| A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose, VLP-Polio medium dose, VLP-Polio high dose - Poliomyelitis | Phase 1 / Phase 2 | Active not recruiting | CanSino Biologics Inc. | 480 | 2024-12-19 | 2026-08-06 |
| Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2), Novel oral poliomyelitis vaccine type 3 (nOPV3) - Poliomyelitis | Phase 1 / Phase 2 | Recruiting | PATH | 2400 | 2024-11-20 | 2025-06-03 |
| Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults EV68-228-N, Placebo for EV68-228-N - Enterovirus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 36 | 2024-06-26 | 2026-05-04 |
| A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio), Inactivated poliomyelitis vaccine (IPOL), VLP-Polio - Poliomyelitis | Phase 1 | Completed | CanSino Biologics Inc. | 72 | 2024-01-15 | 2024-12-04 |
| Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated - Hand, Foot and Mouth Disease, Herpangina | Phase 1 / Phase 2 | Completed | Sinovac Biotech Co., Ltd | 744 | 2023-09-20 | 2026-06-26 |
| A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 1 | Unknown | LG Chem | 42 | 2023-07-17 | 2023-07-19 |
| Alleviation of Common Cold Symptoms Wintergreen Throat Spray and Aspirin Tablet, Aspirin Throat Spray and Placebo Tablet, Wintergreen Throat Spray and Placebo Tablet - Common Cold, Pharyngitis | Phase 1 | Completed | Applied Biological Laboratories Inc | 157 | 2022-05-25 | 2024-01-16 |
| Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain - Poliomyelitis | Phase 1 | Unknown | University of Vermont | 19 | 2022-04-01 | 2023-11-29 |
| Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy Volunteers 2-Deoxyglucose, Placebo - Acute Nasopharyngitis | Phase 1 | Completed | G.ST Antivirals GmbH | 45 | 2022-03-03 | 2023-10-12 |
| First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers. CUR-N399, Placebo - Pulmonary Disease, Chronic Obstructive, Enterovirus Infections | Phase 1 | Completed | Curovir AB | 74 | 2021-07-22 | 2022-03-23 |
| Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1) - Poliomyelitis | Phase 1 | Completed | PATH | 226 | 2021-03-26 | 2024-11-20 |
| PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers PRV-101, Placebo - Viral; Infection, Coxsackie(Virus) | Phase 1 | Completed | Provention Bio, Inc. | 32 | 2020-12-14 | 2022-07-25 |
| Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects IN-B001 EV71 A dose, IN-B001 CVA16 B dose, IN-B001 Bivalent C dose - Hand, Foot and Mouth Disease | Phase 1 | Unknown | HK inno.N Corporation | 30 | 2020-12-01 | 2020-11-20 |
| Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults Inactivated Poliomyelitis Vaccine (IPV), E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant), Bivalent Oral Polio Vaccine (bOPV) - Polio | Phase 1 | Completed | PATH | 87 | 2020-01-22 | 2022-09-06 |
| Safety & Immunogenicity of Enterovirus Type 71 Vaccine in Healthy Adults and Children 6-71months Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell) - Hand Foot & Mouth Disease | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 430 | 2019-12-24 | 2021-02-02 |
| Safety and Immunogenicity of CJ-40010 in Healthy Subjects CJ-40010 EV71 vaccine A dose, CJ-40010 EV71 vaccine B dose, CJ-40010 CVA16 vaccine C dose - Hand, Foot and Mouth Disease | Phase 1 | Unknown | HK inno.N Corporation | 60 | 2019-12-02 | 2019-12-03 |
Showing 20 of 53. Sign in to see all of them.
Poliomyelitis (22) · Hand, Foot and Mouth Disease (12) · Common Cold (9) · Enterovirus Infections (9) · Coxsackievirus Infections (3) · Diphtheria (3) · Tetanus (3) · Whooping Cough (3) · Haemophilus Infections (2) · Hepatitis B (2) · Herpangina (2) · Infections (2) · Virus Diseases (2) · Breast Neoplasms (1) · Cough (1)
RNA Virus Infections (52) · Infections (51) · Virus Diseases (51) · Enterovirus Infections (35) · Central Nervous System Diseases (23) · Nervous System Diseases (23) · Neuroinflammatory Diseases (23) · Central Nervous System Infections (22) · Myelitis (22) · Neuromuscular Diseases (22) · Spinal Cord Diseases (22) · Respiratory Tract Diseases (14) · Coxsackievirus Infections (12) · Respiratory Tract Infections (12)
Poliovirus Vaccine, Inactivated (7) · Acetaminophen (1) · Adjuvants, Pharmaceutic (1) · Aging (1) · Aspirin (1) · Camphor (1) · Deoxyglucose (1) · Dextromethorphan (1) · Fluzone High-Dose (1) · Hepatitis A Vaccines (1) · Ipilimumab (1) · Oxymetazoline (1) · Phenylephrine (1) · Poliovirus Vaccine, Oral (1) · Sodium Chloride (1)
Sinovac Biotech Co., Ltd (5) · Jiangsu Province Centers for Disease Control and Prevention (4) · GlaxoSmithKline (3) · Institute of Medical Biology, Chinese Academy of Medical Sciences (3) · PATH (3) · CanSino Biologics Inc. (2) · HK inno.N Corporation (2) · LG Chem (2) · Pauline Verdijk (2) · University of Vermont (2) · Viralytics (2) · Applied Biological Laboratories Inc (1) · Chinese Academy of Medical Sciences (1) · Curovir AB (1) · Eli Lilly and Company (1)
China (14) · United States (9) · Belgium (4) · Australia (3) · South Korea (3) · Bangladesh (2) · Canada (2) · Poland (2) · Austria (1) · Finland (1) · Germany (1) · India (1) · Indonesia (1) · Netherlands (1) · Panama (1)
Fengcai Zhu, Master (4) · Beth Kirkpatrick, M.D. (2) · Pauline Verdijk, PhD (2) · Arlene Sena, MD (1) · Ayan Dey, Ph.D (1) · Boris Chern, MD (1) · C P Fung, M.D. (1) · Chia-Chyi Liu, Ph.D. (1) · Christina Chang, Dr (1) · Cornelia Dekker, MD (1) · Dr Hitt Sharma, MBBS MBA (1)
PMID 22426327, PMID 24260259, PMID 32867698, PMID 22634437, PMID 23372725, PMID 23541623, PMID 24063976, PMID 24278177, PMID 25043278, PMID 26873055, PMID 28194449, PMID 28866779, PMID 29063860, PMID 30249424, PMID 31174831, PMID 35135601, PMID 35367069, PMID 36651961, PMID 36746739, PMID 38218668, PMID 38369573, PMID 39602479, PMID 40101848, PMID 40126012, PMID 40818478
2017 (1), 2019 (1), 5UM1AI148684-04 (1), R01AI130398 (1)